Single drug dose effective after testicular cancer surgery

Key points
- After surgery, a single dose of carboplatin appears to be just as effective in preventing relapse as three weeks of radiation therapy in men with early-stage Testicular cancer, according to the findings of a study published in this week's issue of The Lancet.
- Padraig Warde and Mary Gospodarowicz, from the University of Toronto, caution against adopting carboplatin as standard follow-up treatment after surgery for early-stage Testicular cancer because surveillance alone seems to be a safe option.
- Although radiotherapy has long been the accepted treatment approach, research has suggested that it may increase the risk of later developing other types of cancer and cardiovascular disease.
- Bart's and the London Hospital in the UK, and colleagues included 1,477 patients with stage I Testicular cancer from 70 hospitals in 14 countries treated between 1996 and 2001.
After surgery, a single dose of carboplatin appears to be just as effective in preventing relapse as three weeks of radiation therapy in men with early-stage Testicular cancer, according to the findings of a study published in this week's issue of The Lancet. Carboplatin also appears to be associated with less severe adverse effects and lower risk of developing a tumor in the other testicle.
Although radiotherapy has long been the accepted treatment approach, research has suggested that it may increase the risk of later developing other types of cancer and cardiovascular disease. Based on preliminary study findings that found one course of carboplatin is as effective as radiation, Dr. R. T. D. Oliver and colleagues initiated a trial comparing the two strategies.
Oliver, from St. Bart's and the London Hospital in the UK, and colleagues included 1,477 patients with stage I Testicular cancer from 70 hospitals in 14 countries treated between 1996 and 2001. The analysis included 885 men randomly assigned to radiotherapy and 560 to carboplatin. The subjects were followed for an average of four years.
Testicular cancer Definition Testicular cancer is an abnormal, rapid, and invasive growth of cancerous (malignant) cells in the testicles (male sex glands adjacent to the penis). The relapse-free rate at three years was 95.9 percent in the radiation group and 94.8 percent in the carboplatin group, a nonsignificant difference. New, second primary testicular germ-cell tumors developed in 10 patients treated with radiation and two treated with carboplatin. One testicular cancer-related death occurred in the radiation group.
There were no significant differences at two years in gonadal function as measured by hormone levels. Although adverse events were more common at 72 hours in the carboplatin group, carboplatin was associated with less lethargy over the next few of months and a more rapid return to work.
"This trial has shown the non-inferiority of carboplatin to radiotherapy in the treatment of stage I seminoma," the authors conclude. They add, "These findings need to be confirmed beyond four years' follow-up."
Testicular cancer Symptoms
- Enlargement of a testicle or a change in the way it feels
- Lump or swelling in either testicle
- Dull ache in the back or lower abdomen
- Gynecomastia (excessive development of male breast tissue), this can also occur normally in adolescent males, in whom it is not a symptom of testicular cancer
- Testicular discomfort/pain or a feeling of heaviness in the scrotum
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsMultiple types of resistance to new lung cancer drug identified
After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors…
5 May 2015
NewsToxic mushroom-based drug may help battle colorectal cancer
For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an…
23 April 2015
NewsNew signaling pathway discovered in HER2-positive breast cancer, and 2 powerful drug targets
One of the most promising ideas in cancer treatment is to apply a lesson learned in the fight against AIDS (Acquired Immune Deficiency Syndrome): simultaneously attacking a pathological process at different points of…







